SciELO - Scientific Electronic Library Online

 
vol.107 número6Obscure gastrointestinal bleeding: which factors are associated with positive capsule endoscopy findings? índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Revista Española de Enfermedades Digestivas

versión impresa ISSN 1130-0108

Rev. esp. enferm. dig. vol.107 no.6 Madrid jun. 2015

 

EDITORIAL

 

Capsule reading is resources consuming. How can we make the best of it?

Leer cápsulas consume tiempo y recursos. ¿Cómo podemos rentabilizarlo?

 

 

Cristina Carretero, César Prieto-Frías and Miguel Muñoz-Navas

Department of Digestive Diseases. Clínica Universidad de Navarra. Pamplona. IdiSNA (Instituto de Investigación Sanitaria de Navarra). Pamplona, Navarra. Spain

 

 

Obscure gastrointestinal bleeding (OGIB) is defined as a recurrent or persistent bleeding where gastroscopy and colonoscopy studies fail to identify an origin, and represents approximately 5% of all digestive bleeding (1). When symptoms include iron deficiency anemia or a positive fecal occult blood test OGIB is qualified as occult, whereas the term overt OGIB is used for presentations with melena or hematochezia (2).

The small bowel is most commonly (80%) the origin of OGIB (2) -for example, Meckel's diverticulum, Crohn's disease or tumors (1). However, a non-negligible percentage of patients may remain underdiagnosed during the initial endoscopy, potential causes may include overlooked gastric or colonic lesions (e.g., esophagitis, Cameron ulcers, portal hypertension-related gastropathy, and angiodysplasia) (3). Because of this, some authors suggest performing a second look gastroscopy (4) and colonoscopy before attempting any further etiologic studies (3). However, studies such as the one reported by Vlachogiannakos have shown that such repeats are not cost-effective (5), at least on a routine basis, and only recommend their performance when suspicion of a previously overlooked lesion is high, when the initial endoscopy was not carried out by an expert endoscopist or with the appropriate equipment, and when poor mucosal preparation impaired mucosal visualization (6).

Once a gastric and/or colonic origin has been ruled out, since 2001 we have capsule endoscopy and balloon enteroscopy available for the study of the small bowel. Both techniques have proven useful for OGIB, and obtained similar results, with a diagnostic accuracy of 59.4% (7) or 61.7% (8) vs. 55.5%, respectively, which is clearly superior to push enteroscopy (26%) (9) and other modalities such as barium follow-through (10) and enteroclysis (11), with even poorer results. Another technique still used by some centers is intraoperative enteroscopy, a highly invasive technique entailing high morbidity and even mortality (12)

Recently, ESGE has suggested a new diagnostic algorithm for OGIB where capsule enteroscopy is first-choice, and assisted enteroscopy (balloon, double balloon, other assisted methods) is considered first-line only when capsule endoscopy is contraindicated or unavailable (13), based on the procedure's safety profile, low invasiveness, and ability to visualize the whole bowel (14).

However, we must bear in mind that capsule endoscopy uses up lots of resources, both economic and human. Particularly for overt OGIB, early capsule endoscopy and reading facilitates decision making at the expense of modifying schedules and routine task assignments at endoscopy units, which represents additional human costs.

In order to optimize the cost-benefit ratio the highest efficiency possible should be sought by priorizing access to testing for patients with potentially greater benefits. To this end, the ability to predict which procedures will find lesions suggestive of an origin for OGIB would be desirable, hence the importance of studies with this aim as the one by Ribeiro et al. (15), published in the present issue of The Spanish Journal of Gastroenterology (Revista Española de Enfermedades Digestivas).

Prior papers on this topic are heterogeneous and obtain disparaging conclusions. The most widely studied variable is type of bleeding, and while most conclude that capsules achieve a better diagnostic yield in patients with overt OGIB as compared to occult OGIB (16-18), such association could not always be ascertained (19,20). It has also been shown that the shorter the time between bleeding and procedure, the higher the diagnostic yield (16,21,22), such that patients deriving the most benefit would be those with overt OGIB, particularly when active at the time of examination (in such cases diagnostic yield is above 90%), and that causal lesions are more difficult to find likely found as time goes on, particularly after a two-week threshold following active bleeding (23).

In addition to the above, other predictive factors have been described, including age, use of oral anticoagulation, liver comorbidity (18), male gender, hospitalization, number of previous endoscopic procedures, transfusion needs, and connective tissue disorders (23,24). However, other studies (20,25) find no differences in many of these variables, hence we are still lacking clear evidence on factors associated with positive findings.

In this issue Ribeiro et al. attempt to elucidate this question. Their work is notable for their use of a previously described classification to define positive findings (26), such that lesions hardly ever give rise to diagnostic doubt and results are therefore more readily reproducible. The authors found that overt OGIB active at the time of examination, transfusion requirements, and prior therapy with nonsteroidal anti-inflammatory drugs are independent predictive factors for positive findings with capsule endoscopy. The joint inclusion in one study of variables reported more frequently than in other studies increases the validity of their results.

It is important to assess that these results be in their proper context. First, it seems appropriate to differentiate between non-modifiable predictors (age, sex, comorbidity, etc.) and circumstantial predictors (transfusion needs, number of prior endocopies). The role of the capsule in the diagnostic process of OGIB is somewhat dynamic, and will likely change in upcoming years with new evidence. Therefore, patient circumstances at the time of the procedure will also vary. For example, as the authors point out in their discussion, the mean number of endoscopies performed prior to capsule endoscopy will likely be lower as the procedure may now be more readily accessible. Results will be more easily generalized to the extent predictor variables are based on stable, non-modifiable factors.

Secondly, this type of study is key for taking a further step in the search for higher efficiency, and identifying factors that may predict changes in the management of patients with OGIB. Neu et al. (10) demonstrated that while type and number of findings during capsule endoscopy are determinant of subsequent management, clinical factors such as lower hemoglobin levels or transfusion needs may similarly predict rebleeding risk or the likeliness of changes in patient management.

In 2009, Dr. Enrique Pérez-Cuadrado ended his editorial (27) on capsule performance in this journal by stating: "We should make the most of this significant resource, namely capsule endoscopy, and improve our routes in the diagnostic challenge posed by GI bleeding. Shall we know how to do it?" In our view, we are on the right track, as studies such as this one by Ribeiro et al. help us priorize procedures by improving diagnostic routes.

 

References

1. Carretero C, Fernandez-Urien I, Betes M, et al. Role of videocapsule endoscopy for gastrointestinal bleeding. World J Gastroenterol 2008;14:5261-4.         [ Links ]

2. Tae CH, Shim KN. Should capsule endoscopy be the first test for every obscure gastrointestinal bleeding? Clin Endosc 2014;47:409-14.         [ Links ]

3. Concha R, Amaro R, Barkin JS. Obscure gastrointestinal bleeding: diagnostic and therapeutic approach. J Clin Gastroenterol 2007;41:242-51.         [ Links ]

4. Velayos B, Herreros de Tejada A, Fernandez L, et al. Upper gastrointestinal findings detected by capsule endoscopy in obscure gastrointestinal bleeding. Rev Esp Enferm Dig 2009;101:11-9.         [ Links ]

5. Vlachogiannakos J, Papaxoinis K, Viazis N, et al. Bleeding lesions within reach of conventional endoscopy in capsule endoscopy examinations for obscure gastrointestinal bleeding: is repeating endoscopy economically feasible? Dig Dis Sci 2011;56:1763-8.         [ Links ]

6. Raju GS, Gerson L, Das A, et al. American Gastroenterological Association (AGA) Institute technical review on obscure gastrointestinal bleeding. Gastroenterology 2007;133:1697-717.         [ Links ]

7. Liao Z, Gao R, Xu C, et al. Indications and detection, completion, and retention rates of small-bowel capsule endoscopy: A systematic review. Gastrointest Endosc 2010;71:280-6.         [ Links ]

8. Teshima CW, Kuipers EJ, van Zanten SV, et al. Double balloon enteroscopy and capsule endoscopy for obscure gastrointestinal bleeding: An updated meta-analysis. J Gastroenterol Hepatol 2011;26:796-801.         [ Links ]

9. Triester SL, Leighton JA, Leontiadis GI, et al. A meta-analysis of the yield of capsule endoscopy compared to other diagnostic modalities in patients with obscure gastrointestinal bleeding. Am J Gastroenterol 2005;100:2407-18.         [ Links ]

10. Neu B, Ell C, May A, Schmid E, et al. Capsule endoscopy versus standard tests in influencing management of obscure digestive bleeding: Results from a German multicenter trial. Am J Gastroenterol 2005;100:1736-42.         [ Links ]

11. Tang SJ, Haber GB. Capsule endoscopy in obscure gastrointestinal bleeding. Gastrointest Endosc Clin N Am 2004;14:87-100.         [ Links ]

12. Monsanto P, Almeida N, Lérias C, et al. Is there still a role for intraoperative enteroscopy in patients with obscure gastrointestinal bleeding? Rev Esp Enferm Dig 2012;104:190-6.         [ Links ]

13. Pennazio M, Spada C, Eliakim R, et al. Small-bowel capsule endoscopy and device-assisted enteroscopy for diagnosis and treatment of small-bowel disorders: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. Endoscopy 2015;47:352-86.         [ Links ]

14. Baptista V, Marya N, Singh A, et al. Continuing challenges in the diagnosis and management of obscure gastrointestinal bleeding. World J Gastrointest Pathophysiol 2014;5:523-33.         [ Links ]

15. Ribeiro I, Pinho R, Rodrigues A, et al. Obscure gastrointestinal bleeding: Which factors are associated with positive capsule endoscopy findings? Rev Esp Enferm Dig 2015; 107:334-9.         [ Links ]

16. Pennazio M, Santucci R, Rondonotti E, et al. Outcome of patients with obscure gastrointestinal bleeding after capsule endoscopy: Report of 100 consecutive cases. Gastroenterology 2004;126:643-53.         [ Links ]

17. Carey EJ, Leighton JA, Heigh RI, et al. A single-center experience of 260 consecutive patients undergoing capsule endoscopy for obscure gastrointestinal bleeding. Am J Gastroenterol 2007;102:89-95.         [ Links ]

18. Sidhu R, Sanders DS, Sakellariou VP, et al. Capsule endoscopy and obscure gastrointestinal bleeding: are transfusion dependence and comorbidity further risk factors to predict a diagnosis? Am J Gastroenterol 2007;102:1329-30.         [ Links ]

19. Sidhu R, Sanders DS, Kapur K, et al. Factors predicting the diagnostic yield and intervention in obscure gastrointestinal bleeding investigated using capsule endoscopy. J Gastrointestin Liver Dis 2009;18:273-8.         [ Links ]

20. Selby W. Can clinical features predict the likelihood of finding abnormalities when using capsule endoscopy in patients with GI bleeding of obscure origin? Gastrointest Endosc 2004;59:782-7.         [ Links ]

21. Singh A, Marshall C, Chaudhuri B, et al. Timing of video capsule endoscopy relative to overt obscure GI bleeding: implications from a retrospective study. Gastrointest Endosc 2013;77:761-6.         [ Links ]

22. Yamada A, Watabe H, Kobayashi Y, et al. Timing of capsule endoscopy influences the diagnosis and outcome in obscure-overt gastrointestinal bleeding. Hepatogastroenterology 2012;59:676-9.         [ Links ]

23. Lepileur L, Dray X, Antonietti M, et al. Factors associated with diagnosis of obscure gastrointestinal bleeding by video capsule enteroscopy. Clin Gastroenterol Hepatol 2012;10:1376-80.         [ Links ]

24. Shahidi NC, Ou G, Svarta S, et al. Factors associated with positive findings from capsule endoscopy in patients with obscure gastrointestinal bleeding. Clin Gastroenterol Hepatol 2012;10:1381-5.         [ Links ]

25. Lee BJ, Chun HJ, Koo JS, et al. Analysis of the factors that affect the diagnostic yield of capsule endoscopy in patients with obscure gastrointestinal bleeding. Korean J Gastroenterol 2007;49:79-84.         [ Links ]

26. Saurin JC, Delvaux M, Vahedi K, et al. Clinical impact of capsule endoscopy compared to push enteroscopy: 1-year follow-up study. Endoscopy 2005;37:318-23.         [ Links ]

27. Pérez-Cuadrado Martínez E. Capsule endoscopy - are we making the most of all its benefits? Rev Esp Enferm Dig 2009;101:1-10.         [ Links ]

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons